Academic Journal
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19
العنوان: | In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19 |
---|---|
المؤلفون: | Sacramento, Carolina Q, Fintelman-Rodrigues, Natalia, Temerozo, Jairo R, Da Silva, Aline de Paula Dias, Dias, Suelen da Silva Gomes, da Silva, Carine dos Santos, Ferreira, André C, Mattos, Mayara, Pão, Camila R R, de Freitas, Caroline S, Soares, Vinicius Cardoso, Hoelz, Lucas Villas Bôas, Fernandes, Tácio Vinício Amorim, Branco, Frederico Silva Castelo, Bastos, Mônica Macedo, Boechat, Núbia, Saraiva, Felipe B, Ferreira, Marcelo Alves, Jockusch, Steffen, Wang, Xuanting, Tao, Chuanjuan, Chien, Minchen, Xie, Wei, Patel, Dinshaw, Garzia, Aitor, Tuschl, Thomas, Russo, James J, Rajoli, Rajith K R, Pedrosa, Carolina S G, Vitória, Gabriela, Souza, Letícia R Q, Goto-Silva, Livia, Guimarães, Marilia Zaluar, Rehen, Stevens K, Owen, Andrew, Bozza, Fernando A, Bou-Habib, Dumith Chequer, Ju, Jingyue, Bozza, Patrícia T, Souza, Thiago Moreno L |
المساهمون: | Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro, Coordenaçaõ de Aperfeiçoamento de Pessoal de Nível Superior—Brasil, National Institutes of Science and Technology Program, Carlos Morel, Oswaldo Cruz Foundation, Inova Program, Jack Ma Foundation |
المصدر: | Journal of Antimicrobial Chemotherapy ; volume 76, issue 7, page 1874-1885 ; ISSN 0305-7453 1460-2091 |
بيانات النشر: | Oxford University Press (OUP) |
سنة النشر: | 2021 |
الوصف: | Background Current approaches of drug repurposing against COVID-19 have not proven overwhelmingly successful and the SARS-CoV-2 pandemic continues to cause major global mortality. SARS-CoV-2 nsp12, its RNA polymerase, shares homology in the nucleotide uptake channel with the HCV orthologue enzyme NS5B. Besides, HCV enzyme NS5A has pleiotropic activities, such as RNA binding, that are shared with various SARS-CoV-2 proteins. Thus, anti-HCV NS5B and NS5A inhibitors, like sofosbuvir and daclatasvir, respectively, could be endowed with anti-SARS-CoV-2 activity. Methods SARS-CoV-2-infected Vero cells, HuH-7 cells, Calu-3 cells, neural stem cells and monocytes were used to investigate the effects of daclatasvir and sofosbuvir. In silico and cell-free based assays were performed with SARS-CoV-2 RNA and nsp12 to better comprehend the mechanism of inhibition of the investigated compounds. A physiologically based pharmacokinetic model was generated to estimate daclatasvir’s dose and schedule to maximize the probability of success for COVID-19. Results Daclatasvir inhibited SARS-CoV-2 replication in Vero, HuH-7 and Calu-3 cells, with potencies of 0.8, 0.6 and 1.1 μM, respectively. Although less potent than daclatasvir, sofosbuvir alone and combined with daclatasvir inhibited replication in Calu-3 cells. Sofosbuvir and daclatasvir prevented virus-induced neuronal apoptosis and release of cytokine storm-related inflammatory mediators, respectively. Sofosbuvir inhibited RNA synthesis by chain termination and daclatasvir targeted the folding of secondary RNA structures in the SARS-CoV-2 genome. Concentrations required for partial daclatasvir in vitro activity are achieved in plasma at Cmax after administration of the approved dose to humans. Conclusions Daclatasvir, alone or in combination with sofosbuvir, at higher doses than used against HCV, may be further fostered as an anti-COVID-19 therapy. |
نوع الوثيقة: | article in journal/newspaper |
اللغة: | English |
DOI: | 10.1093/jac/dkab072 |
الاتاحة: | http://dx.doi.org/10.1093/jac/dkab072 http://academic.oup.com/jac/article-pdf/76/7/1874/38693683/dkab072.pdf |
Rights: | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model |
رقم الانضمام: | edsbas.66D7A0DB |
قاعدة البيانات: | BASE |
DOI: | 10.1093/jac/dkab072 |
---|